Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.

adavosertib head and neck cancer mitotic catastrophe prexasertib

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Jan 2020
Historique:
received: 03 12 2019
revised: 20 01 2020
accepted: 23 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: epublish

Résumé

Head and neck squamous cell carcinomas (HNSCC) affect more than 800,000 people annually worldwide, causing over 15,000 deaths in the US. Among HNSCC cancers, human papillomavirus (HPV)-negative HNSCC has the worst outcome, motivating efforts to improve therapy for this disease. The most common mutational events in HPV-negative HNSCC are inactivation of the tumor suppressors

Identifiants

pubmed: 32012873
pii: cancers12020306
doi: 10.3390/cancers12020306
pmc: PMC7072436
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : R50 CA211479
Pays : United States
Organisme : NIH HHS
ID : R01 DK108195
Pays : United States
Organisme : NIH HHS
ID : R21 CA181287
Pays : United States
Organisme : NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211479
Pays : United States

Déclaration de conflit d'intérêts

Barbara Burtness reports consulting fees from Astra-Zeneca. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2140-5
pubmed: 26858460
Trends Genet. 2013 Jul;29(7):394-402
pubmed: 23537585
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gastroenterology. 2015 Dec;149(7):1872-1883.e9
pubmed: 26344056
Mol Cell. 2004 Sep 10;15(5):799-811
pubmed: 15350223
Cell. 2015 Aug 27;162(5):944-7
pubmed: 26317463
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
J Clin Oncol. 2015 Oct 20;33(30):3409-15
pubmed: 25964244
J Clin Oncol. 2016 Dec 20;34(36):4371-4380
pubmed: 27601554
Mol Biol Cell. 1995 Apr;6(4):371-85
pubmed: 7626804
Lancet Oncol. 2019 Sep;20(9):1295-1305
pubmed: 31351869
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cancer Res. 2017 Jul 15;77(14):3870-3884
pubmed: 28490518
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cell Mol Life Sci. 2013 Feb;70(4):661-87
pubmed: 22864622
Nat Genet. 2003 Mar;33(3):357-65
pubmed: 12567188
J Clin Oncol. 2016 May 20;34(15):1764-71
pubmed: 27044938
Clin Cancer Res. 2018 Jul 15;24(14):3263-3272
pubmed: 29643063
Trends Cell Biol. 1997 Feb;7(2):63-8
pubmed: 17708908
Nat Chem Biol. 2014 Apr;10(4):305-12
pubmed: 24584101
Int J Radiat Biol. 2011 Nov;87(11):1135-46
pubmed: 21913819
Cancer Discov. 2012 Jun;2(6):524-39
pubmed: 22628408
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
J Cell Sci. 2015 Feb 15;128(4):607-20
pubmed: 25609713
Clin Cancer Res. 2019 Apr 1;25(7):2278-2289
pubmed: 30563935
Mol Cancer Ther. 2016 Oct;15(10):2486-2497
pubmed: 27507850
Clin Cancer Res. 2019 Oct 15;25(20):6127-6140
pubmed: 31409614
Oncotarget. 2017 Mar 21;8(12):19156-19171
pubmed: 27863405
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
JAMA Oncol. 2016 Feb;2(2):253-60
pubmed: 26633733
J Clin Oncol. 2015 Jul 20;33(21):2399-404
pubmed: 26077240
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Science. 2008 Jun 20;320(5883):1655-8
pubmed: 18566290
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nature. 2008 Sep 4;455(7209):119-23
pubmed: 18615013
Cancer Res. 2015 Apr 1;75(7):1527-36
pubmed: 25634208
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Cancer Biol Ther. 2010 Apr 1;9(7):514-22
pubmed: 20107315
Mol Cancer Res. 2019 May;17(5):1115-1128
pubmed: 30679201
Clin Cancer Res. 2019 Jun 1;25(11):3430-3442
pubmed: 30755439
Breast Cancer Res. 2019 Sep 6;21(1):104
pubmed: 31492187
J Cell Biol. 2019 Sep 2;218(9):2865-2875
pubmed: 31366665
Nat Struct Mol Biol. 2012 Sep;19(9):930-7
pubmed: 22885324
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
Clin Cancer Res. 2018 Jun 15;24(12):2740-2748
pubmed: 29535125
Invest New Drugs. 2019 Nov 9;:
pubmed: 31707688
Clin Cancer Res. 2014 Aug 15;20(16):4274-88
pubmed: 25125259
Cancer Res. 2013 Oct 15;73(20):6289-98
pubmed: 23980093
J Cell Sci. 2004 May 15;117(Pt 12):2523-31
pubmed: 15128871
Lancet Oncol. 2013 Sep;14(10):e425-35
pubmed: 23993387

Auteurs

Alexander Y Deneka (AY)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Department of Biochemistry and Biotechnology, Kazan Federal University, 420000 Kazan, Russia.

Margret B Einarson (MB)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

John Bennett (J)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Department of Biology, Chestnut Hill College, Philadelphia, PA 19118, USA.

Anna S Nikonova (AS)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Mohamed Elmekawy (M)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.

Yan Zhou (Y)

Bioinformatics and Biostatistics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Jong Woo Lee (JW)

Section of Medical Oncology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA.

Barbara A Burtness (BA)

Section of Medical Oncology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA.

Erica A Golemis (EA)

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Classifications MeSH